The US FDA has scheduled an Oncologic Drugs Advisory Committee to discuss biologics license application 125547, necitumumab injection, application submitted by Eli Lilly and Company. The proposed indication for this product is in combination with gemcitabine and cisplatin for first-line treatment of patients with locally advanced or metastatic squamous non-small cell lung cancer.